CompletedNot applicableNCT04595617
Anti-αIIbβ3 Immunization in Glanzmann Thrombasthenia: Prevalence and Associated Risk Factors: Thrombasthenia Anti-αIIbβ3 Antibodies Study (TAAS)
Studying Glanzmann thrombasthenia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University Hospital, Bordeaux
- Principal Investigator
- Mathieu FIOREUniversity Hospital, Bordeaux
- Intervention
- Antibodies screening(biological)
- Enrollment
- 28 enrolled
- Eligibility
- 6 years · All sexes
- Timeline
- 2021 – 2023
Study locations (7)
- CHU Bordeaux - Hôpital Haut-Lévêque, Bordeaux, France
- CHU Bordeaux - Hôpital Pellegrin, Bordeaux, France
- Hôpital Bicêtre, APHP, Le Kremlin-Bicêtre, France
- Hôpital la Timone, APHM, Marseille, France
- CHU Nîmes, Nîmes, France
- CHU Strasbourg, Strasbourg, France
- CHU Toulouse, Toulouse, France
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04595617 on ClinicalTrials.govOther trials for Glanzmann thrombasthenia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07136857Eptacog Beta in Glanzmann's (HeT_LFB-Strength-Study_FID531)Emory University
- RECRUITINGNCT06820515ATHNdataset RegistryAmerican Thrombosis and Hemostasis Network
- RECRUITINGNANCT04119908Videomicroscopy for the Prediction of Bleeding in Constitutional Haemorrhagic DiseasesUniversity Hospital, Lille
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06211634A Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Glanzmann ThrombastheniaHemab ApS
- RECRUITINGNCT00230165The Genetics and Functional Basis of Inherited Platelet, White Blood Cell, Red Blood Cell, and Blood Clotting Disorders.Rockefeller University